FDA OKs CTI's software

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

CTI Mirada Solutions, a subsidiary of CTI Molecular Imaging Inc., has been awarded FDA 510k clearance to market Scenium, a new quantification tool for the analysis of neurological positron emission tomography (PET) scans.
   
Scenium display and analysis software has been developed to aid clinicians in accurate assessment and quantification of dementia and other neurological diseases, CTI said. Initially developed for use in PET studies with fluorodeoxyglucose (FDG), Scenium has the potential to be used with other PET molecular imaging agents in the future, CTI said.
   
Based on Mirada's image fusion techniques, Scenium enables clinicians to compare patients' brain scans to standard normal scans, highlighting differences in uptake. Multiple anatomical regions are highlighted for quick assessment of an image and quantitative comparison with other images and integration into the current reporting workflow of the imaging center.
   
CTI said the software will be available as a plug-in to a wide variety of viewing workstations, and also for use on a standard PC. Scenium is planned for release this spring. The software will be distributed by CTI PETNET, as well as Mirada's OEM/PACS partners.